Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
XmAb20717 is a bispecific antibody that targets both PD-1 (PDCD1) and CTLA4, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|XmAb20717||XmAb 20717|Vudalimab||CTLA4 Antibody 18 Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67||XmAb20717 (Vudalimab) is a bispecific antibody that targets both PD-1 (PDCD1) and CTLA4, potentially resulting in increased anti-tumor immune response (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03517488||Phase I||XmAb20717||A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)||Recruiting||USA||0|